TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04546399

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study: NCT03279536

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral lactoferrin
Description: Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TDI of LMW iron dextran
Description: Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
Study: NCT04572399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV Light Treatment
Description: UV light therapy administered while patient is mechanically ventilated
Study: NCT04186117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample before any treatment
Study: NCT03930238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA MapTrek
Description: The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
Study: NCT04546399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study: NCT01804686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
Study: NCT03930238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Fitbit Only
Study: NCT02181751

Intervention type: OTHER
Intervention: Trauma Focused Cognitive Behavioural Therapy Group
Description: Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
Study: NCT03296423

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination
Description: Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
Study: NCT03003884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose plus supplemental doses as necessary.
Study: NCT01763489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applicability Assessment
Description: assess the applicability of a trial using the ASSIST tool or the synopsis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applicability Assessment
Description: assess the applicability of a trial using the ASSIST tool or the synopsis
Study: NCT04422509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lanadelumab
Description: single dose, or two doses administered iv

Intervention type: OTHER
Group type: OTHER
Intervention: regular care
Description: no lanadelumab administration, treated according to regular care
Study: NCT00825643

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
Study: NCT00421096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area
Study: NCT01535196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigantol oil and MCT oil
Description: Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vigantol oil and MCT oil
Description: Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
Study: NCT00421096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
Study: NCT03881813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic retainers
Description: Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic retainers
Description: Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
Study: NCT03139968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (sham) radiation absorbing drape (RADPAD®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (sham) radiation absorbing drape (RADPAD®)
Study: NCT01171066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tasman CPAP system
Description: Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
Study: NCT01762358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Khalifa's therapy
Description: One hour of Khalifa's therapy which is specially applied pressure to the skin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Twelve times standardized Physiotherapy
Study: NCT04623736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quitSTART
Description: All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location.
Study: NCT01386346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
Study: NCT06257108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Class II Cavity Restorations
Description: The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Class II Cavity Restorations
Description: The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.
Study: NCT02767193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCV3
Description: Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4
Study: NCT04546399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT03616535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: The investigators will provide participants with tablets to play brain games.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The investigators will provide participants with foot peddlers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined cognitive and exercise training
Description: The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
Study: NCT04508348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk
Description: Exclusive Human Milk diet

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: This diet will include mother's milk and/or formula
Study: NCT04744883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Description: 2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
Study: NCT04546399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT
Study: NCT01631825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT02176018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan and quinidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03300661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Style
Description: After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
Study: NCT01116440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: 0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
Study: NCT02767193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCV3 with PEG-INF
Description: Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
Study: NCT04744883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
Study: NCT02767193

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with PEG-INF
Description: Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
Study: NCT01383525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Selective Trabeculoplasty device
Description: Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
Study: NCT02203565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dakin's solution
Description: Applied topically
Study: NCT04744883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Therapy (MT)
Description: Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
Study: NCT02203565

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT02485938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Description: Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)